Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kalevi Pulkkanen"'
Autor:
Petteri Hervonen, Antti Jekunen, Timo Marttila, Teppo Huttunen, Vesa Kataja, Marjaana Luukkaa, Pirkko-Liisa Kellokumpu-Lehtinen, Tapio Utriainen, Katariina Klintrup, Kalevi Pulkkanen, Anna-Liisa Kautio, Markku J Leskinen
Publikováno v:
Anticancer research. 40(12)
Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Pati
Autor:
Luke T. Nordquist, Avivit Peer, Kalevi Pulkkanen, Oliver Sartor, Stefano Severi, Daniel Keizman, Giuseppe Procopio, Camilla Thellenberg Karlsson, Stephen Frank, Neil Mariados, Eli Rosenbaum, Rui Li, María José Méndez Vidal, José Trigo, Volker Wagner, Daniel Heinrich, Lucia Trandafir
Publikováno v:
The Prostate
Background Radium‐223 dichloride (radium‐223) is approved for patients with castration‐resistant prostate cancer (CRPC), symptomatic bone metastases, and no visceral disease using a dosing regimen of 6 injections (55 kBq/kg intravenously; 1 inj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f6d85c7e02c054e6a1514b8ff773c8f
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-163675
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-163675
Autor:
María José Méndez Vidal, Daniel Heinrich, Daniel Keizman, Neil Mariados, Stefano Severi, Luke T. Nordquist, L. Trandafir, Camilla Thellenberg Karlsson, Stephen Frank, Giuseppe Procopio, Eli Rosenbaum, Kalevi Pulkkanen, Jose Manuel Trigo Perez, Rui Li, Avivit Peer, Oliver Sartor, Volker Wagner
Publikováno v:
Journal of Urology. 199
Autor:
Luke T. Nordquist, Neil Mariados, Avivit Peer, Victoria Wagner, G. Procopio, Oliver Sartor, Stefano Severi, C. Thellenberg Karlsson, Eli Rosenbaum, Daniel Keizman, M. J.Méndez Vidal, Rui Li, Kalevi Pulkkanen, J.M. Trigo Perez, Daniel Heinrich, Stephen Frank
Publikováno v:
Annals of Oncology
Background: Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8c26e8b313e55bfc8c38becb7895a55
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-140899
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-140899
Autor:
Luke T. Nordquist, Neil Mariados, Kalevi Pulkkanen, Roujia Li, Daniel Heinrich, Eli Rosenbaum, Volker Wagner, Daniel Keizman, G. Procopio, Stephen Frank, Avivit Peer, C. Thellenberg Karlsson, M.J. Mendez Vidal, Oliver Sartor, J.M. Trigo Perez, Stefano Severi, L. Trandafir
Publikováno v:
European Urology Supplements. 17:e872-e873
Autor:
Luke T. Nordquist, Avivit Peer, Kalevi Pulkkanen, Oliver Sartor, Daniel Keizman, Camilla Thellenberg-Karlsson, Rui Li, María José Méndez Vidal, Paul Schwarzenberger, Neil Mariados, Giuseppe Procopio, Stefano Severi, Jose Manuel Trigo Perez, Stephen Frank
Publikováno v:
Journal of Urology. 195
Autor:
Stefano Severi, Eli Rosenbaum, Rui Li, Daniel Keizman, A. Oliver Sartor, Luke T. Nordquist, L. Trandafir, Volker Wagner, Giuseppe Procopio, Camilla Thellenberg Karlsson, Avivit Peer, Daniel Heinrich, María José Méndez-Vidal, Kalevi Pulkkanen, Neil Mariados, Jose Manuel Trigo Perez, Stephen Frank
Publikováno v:
Journal of Clinical Oncology. 36:178-178
178 Background: Radium-223 (Ra-223) treatment (tx) is indicated for patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) (6 × 55 kBq/kg IV injections [inj]; 1 inj q4wk). Early results of an internati
Publikováno v:
Acta Oncologica. 46:1037-1041
Autor:
Daniel Heinrich, J. Garcia-Vargas, G. Procopio, M.J. Mendez Vidal, Stefano Severi, C. Thellenberg Karlsson, Daniel Keizman, J.M. Trigo Perez, Avivit Peer, Neil Mariados, Oliver Sartor, Luke T. Nordquist, Victoria Wagner, Kalevi Pulkkanen, Stephen Frank, Eli Rosenbaum, Rui Li
Publikováno v:
Annals of Oncology. 27:vi255
Autor:
Markku J Leskinen, Marjaana Luukkaa, Petteri Hervonen, Katariina Klintrup, Ilari Lehtinen, Tapio Utriainen, Kalevi Pulkkanen, Anna-Liisa Kautio, Mikko Taalikka, Antti Jekunen, Timo Marttila, Pirkko-Liisa Kellokumpu-Lehtinen, Vesa Kataja
Publikováno v:
Journal of Clinical Oncology. 34:e16523-e16523
e16523Background: In our Prosty I trial biweekly docetaxel (D) was better tolerated and yielded longer overall survival than standard triweekly D (Kellokumpu-Lehtinen et al. Lancet Oncol 2013;14:11...